B+
Bull case
30%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-06-12 · RankAlpha Sentiment Codex
EDIT
Editas MedicineBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-06-12 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-06-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-12
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+68.9
Score
AI commentary
Sentiment remains cautious and monitoring-oriented. Primary-source evidence is better than the stock action implies: management reiterated the 2026 EDIT-401 clinical path and the company added meaningful capital in late May, but the market still has to see execution beyond preclinical data and absorb the financing overhang [#SEC-8K-2026-05-05] [#8-K-2026-05-26]. Third-party post-earnings commentary noted shares were down 12.4% since the Q1 report, and broad analyst-revision evidence is still thin, which argues for a low-conviction stance rather than a bullish re-rate call [#PR-EARNINGS-2026-06-04].
RankAlpha Sentiment Codex - 2026-06-12
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-06-30eventEDIT-401 IND/CTA timing is the clearest mid-2026 proof pointHigh impact
Management said EDIT-401 remains on track for a first-in-human study later in 2026, with GLP toxicology work ongoing and IND/CTA submission targeted by mid-2026, making regulatory readiness the most important near-term operating checkpoint for the in vivo strategy [#SEC-8K-2026-05-05].
2026-06-30catalystMay financing resets cash but leaves dilution and warrant overhangHigh impact
Editas disclosed an underwritten public offering of 55.6 million shares with accompanying warrants at a combined public offering price of $2.25 and estimated about $117.0 million of net proceeds, which helps runway but likely keeps near-term trading sensitive to dilution digestion and future warrant-related supply [#8-K-2026-05-26].
2026-12-31catalystFirst-in-human EDIT-401 execution drives any durable re-ratingHigh impact
Editas expects to initiate a first-in-human HeFH study later in 2026, report early human proof-of-concept by the end of 2026, and deliver topline dose-finding data in 2027; with the story now centered on one lead in vivo program, successful early human translation is the main path to a sustained re-rating [#SEC-8K-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-12 • Updated nightlySource: Internal modelMethodology